IDH3A

Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial · P50213 · IDH3A on Sugi Atlas →

0 patent compounds predicted against IDH3A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to IDH3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia PHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) PHASE3RECRUITING
Vorasidenib Maintenance for IDH Mutant Astrocytoma PHASE3RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
Phase 2 Study of IDH305 in Low Grade Gliomas PHASE2WITHDRAWN
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy PHASE2SUSPENDED
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas PHASE2COMPLETED
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy PHASE2ACTIVE_NOT_RECRUITING
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. PHASE2NOT_YET_RECRUITING
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation PHASE2ACTIVE_NOT_RECRUITING
A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia PHASE2RECRUITING
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
Olaparib in Recurrent IDH-mutant Glioma PHASE2COMPLETED
Food Effect Study of AG-221 in Healthy Male Subjects PHASE1COMPLETED
CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas EARLY_PHASE1UNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas nanRECRUITING
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients nanUNKNOWN
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma nanNOT_YET_RECRUITING
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas nanCOMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas nanACTIVE_NOT_RECRUITING
Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML nanCOMPLETED
Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma nanNOT_YET_RECRUITING
Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared nanRECRUITING
Surgical Management of Low Grade Glioma nanNOT_YET_RECRUITING
Correlation Between SPECT/CT and IDH Mutation in Brain Glioma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a IDH3A binder may also engage these)

ProteinNameSimilarity
P56471 1.000 P56471 →
P41563 1.000 P41563 →
Q9D6R2 1.000 Q9D6R2 →
Q28480 1.000 Q28480 →
Q99NA5 1.000 Q99NA5 →
Q5R678 1.000 Q5R678 →
Q9VWH4 1.000 Q9VWH4 →
Q93714 1.000 Q93714 →
O13696 0.998 O13696 →
Q9USP8 0.997 Q9USP8 →
P29696 0.997 P29696 →
Q8LG77 0.996 Q8LG77 →
Q945K7 0.995 Q945K7 →
Q54B68 0.995 Q54B68 →
P54354 0.993 P54354 →
Q5E857 0.993 Q5E857 →
Q8LFC0 0.992 Q8LFC0 →
Q5LAB4 0.992 Q5LAB4 →
P93032 0.992 P93032 →
Q6LV25 0.991 Q6LV25 →
Q5PDG2 0.990 Q5PDG2 →
Q65V05 0.990 Q65V05 →
Q8DEE0 0.990 Q8DEE0 →
O94230 0.990 O94230 →
Q8Z9I1 0.990 Q8Z9I1 →
Q326G2 0.990 Q326G2 →
Q7N128 0.990 Q7N128 →
Q55BI2 0.990 Q55BI2 →
Q4QLS3 0.989 Q4QLS3 →
Q8FL76 0.989 Q8FL76 →